Antithrombotic pharmacotherapy after transcatheter aortic valve implantation: an update

References

• Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis. Circulation. 2002;106:3006–3008.
   PubMed Web of Science ®Google Scholar
• Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–1607.
   PubMed Web of Science ®Google Scholar
• Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790–1798.
   PubMed Web of Science ®Google Scholar
• Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187–2198.
   PubMed Web of Science ®Google Scholar
• Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–1620.
   PubMed Web of Science ®Google Scholar
• Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321–1331.
   PubMed Web of Science ®Google Scholar
• Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. [Internet]. 2019. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30883058.
   Web of Science ®Google Scholar
• Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. [Internet. 2019. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30883053.
   PubMed Web of Science ®Google Scholar
• Durko AP, Osnabrugge RL, Van Mieghem NM, et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur Heart J. 2018;39:2635–2642.
   PubMed Web of Science ®Google Scholar
• Piccolo R, Pilgrim T, Franzone A, et al. Frequency, timing, and impact of access-site and non-access-site bleeding on mortality among patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. [Internet]. 2017;10:1436–1446. [cited 2018 Mar 17];Available from: http://linkinghub.elsevier.com/retrieve/pii/S1936879817309603
   PubMed Web of Science ®Google Scholar
• Généreux P, Cohen DJ, Mack M, et al. Incidence, Predictors, and Prognostic Impact of Late Bleeding Complications After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2014;64:2605–2615.
   PubMed Web of Science ®Google Scholar
• Dangas GD, Mehran R. Bleeding After Aortic Valve Replacement Matters. JACC Cardiovasc Interv. 2017;10:1447–1448.
   PubMed Web of Science ®Google Scholar
• Vranckx P, Windecker S, Welsh RC, et al. Thrombo-embolic prevention after transcatheter aortic valve implantation. Eur Heart J. [Internet]. 2017;38:3341–3350. [cited 2018 Jan 20];Available from: http://www.ncbi.nlm.nih.gov/pubmed/29020333
   PubMed Web of Science ®Google Scholar
• Wang J, Yu W, Jin Q, et al. Risk Factors for Post-TAVI Bleeding According to the VARC-2 Bleeding Definition and Effect of the Bleeding on Short-Term Mortality: A Meta-analysis. Can J Cardiol. 2017;33:525–534.
   PubMed Web of Science ®Google Scholar
• Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials. J Am Coll Cardiol. 2011;57:253–269.
   PubMed Web of Science ®Google Scholar
• Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint de fi nitions for transcatheter aortic valve implantation : the valve academic research consortium-2 consensus document. Eur Heart J. 2012;33:2403–2418.
   PubMed Web of Science ®Google Scholar
• Thyregod HGH, Steinbrüchel DA, Ihlemann N, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis. J Am Coll Cardiol. 2015;65:2184–2194.
   PubMed Web of Science ®Google Scholar
• Fanaroff AC, Manandhar P, Holmes DR, et al. Peripheral artery disease and transcatheter aortic valve replacement outcomes. Circ Cardiovasc Interv. 2017 Oct;10(10). pii: e005456. doi: 10.1161/CIRCINTERVENTIONS.117.005456.
   PubMedGoogle Scholar
• Steinvil A, Leshem-Rubinow E, Abramowitz Y, et al. Prevalence and predictors of carotid artery stenosis in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2014;84:1007–1012.
   PubMed Web of Science ®Google Scholar
• Jørgensen TH, Thyregod HGH, Tarp JB, et al. Temporal changes of new-onset atrial fibrillation in patients randomized to surgical or transcatheter aortic valve replacement. Int J Cardiol. 2017;234:16–21.
   PubMed Web of Science ®Google Scholar
• Biviano AB, Nazif T, Dizon J, et al. Atrial Fibrillation Is Associated With Increased Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement. Circ Cardiovasc Interv. 2016;9:e002766.
   PubMed Web of Science ®Google Scholar
• Siontis GCM, Praz F, Lanz J, et al. New-onset arrhythmias following transcatheter aortic valve implantation: a systematic review and meta-analysis. Heart. 2018;104:1208–1215.
   PubMed Web of Science ®Google Scholar
• Rodés-Cabau J, Gutiérrez M, Bagur R, et al. Incidence, predictive factors, and prognostic value of myocardial injury following uncomplicated transcatheter aortic valve implantation. J Am Coll Cardiol. 2011;57:1988–1999.
   PubMed Web of Science ®Google Scholar
• Stefanini GG, Stortecky S, Meier B, et al. Severe aortic stenosis and coronary artery disease. EuroIntervention. 2013;9:S63–S68.
   PubMed Web of Science ®Google Scholar
• Kotronias RA, Kwok CS, George S, et al. Transcatheter aortic valve implantation with or without percutaneous coronary artery revascularization strategy: a systematic review and meta‐analysis. J Am Heart Assoc. 2017;6.
   Web of Science ®Google Scholar
• Witberg G, Regev E, Chen S, et al. The prognostic effects of coronary disease severity and completeness of revascularization on mortality in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. [Internet]. 2017;10:1428–1435. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1936879817309615
   PubMed Web of Science ®Google Scholar
• O’Sullivan CJ, Englberger L, Hosek N, et al. Clinical outcomes and revascularization strategies in patients with low-flow, low-gradient severe aortic valve stenosis according to the assigned treatment modality. JACC Cardiovasc Interv. 2015;8:704–717.
   PubMed Web of Science ®Google Scholar
• Witberg G, Lavi I, Harari E, et al. Effect of coronary artery disease severity and revascularization completeness on 2-year clinical outcomes in patients undergoing transcatether aortic valve replacement. Coron Artery Dis. 2015;26:573–582.
   PubMed Web of Science ®Google Scholar
• Cao D, Chiarito M, Pagnotta P, et al. Coronary revascularisation in transcatheter aortic valve implantation candidates: why, who, when? Interv Cardiol Rev. 2018;13:1.
   Google Scholar
• Van Mieghem NM, van der Boon RM, Faqiri E, et al. Complete revascularization is not a prerequisite for success in current transcatheter aortic valve implantation practice. JACC Cardiovasc Interv. 2013;6:867–875.
   PubMed Web of Science ®Google Scholar
• Nombela-Franco L, Webb JG, de Jaegere PP, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation. 2012;126:3041–3053.
   PubMed Web of Science ®Google Scholar
• Nesbitt WS, Westein E, Tovar-Lopez FJ, et al. A shear gradient–dependent platelet aggregation mechanism drives thrombus formation. Nat Med. 2009;15:665–673.
   PubMed Web of Science ®Google Scholar
• Ranasinghe MP, Peter K, McFadyen JD, et al. Thromboembolic and bleeding complications in transcatheter aortic valve implantation: insights on mechanisms, prophylaxis and therapy. J Clin Med. 2019;8:280.
   Web of Science ®Google Scholar
• Barbanti M, Gulino S, Tamburino C, et al. Antithrombotic therapy following transcatheter aortic valve implantation: what challenge do we face? Expert Rev Cardiovasc Ther. [Internet]. 2016 14:381–389. [cited 2018 Mar 17]; Available from: http://www.tandfonline.com/doi/full/10.1586/14779072.2016.1124760
   PubMed Web of Science ®Google Scholar
• Auffret V, Regueiro A, Del Trigo M, et al. Predictors of early cerebrovascular events in patients with aortic stenosis undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68:673–684.
   PubMed Web of Science ®Google Scholar
• Van Mieghem NM, El Faquir N, Rahhab Z, et al. Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2015;8:718–724.
   PubMed Web of Science ®Google Scholar
• Stortecky S, Windecker S. Stroke: an Infrequent but Devastating Complication in Cardiovascular Interventions. Circulation. [Internet]. 2012 126:2921–2924. [cited 2018 Mar 17]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/23248061
   PubMed Web of Science ®Google Scholar
• Kahlert P, Knipp SC, Schlamann M, et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation. Circulation. 2010;121:870–878.
   PubMed Web of Science ®Google Scholar
• Van Belle E, Hengstenberg C, Lefevre T, et al. Cerebral Embolism During Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2016;68:589–599.
   PubMedGoogle Scholar
• Doerner J, Kupczyk PA, Wilsing M, et al. Cerebral white matter lesion burden is associated with the degree of aortic valve calcification and predicts peri-procedural cerebrovascular events in patients undergoing transcatheter aortic valve implantation (TAVI). Catheter Cardiovasc Interv. 2018;91:774–782.
   PubMed Web of Science ®Google Scholar
• Haussig S, Mangner N, Dwyer MG, et al. Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis. JAMA. 2016;316:592.
   PubMed Web of Science ®Google Scholar
• Schmidt T, Leon MB, Mehran R, et al. Debris heterogeneity across different valve types captured by a cerebral protection system during transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11:1262–1273.
   PubMed Web of Science ®Google Scholar
• Seeger J, Kapadia SR, Kodali S, et al. Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis. Eur Heart J. 2019 May 1;40(17):1334-1340. doi: 10.1093/eurheartj/ehy847.
   PubMedGoogle Scholar
• Teitelbaum M, Kotronias RA, Sposato LA, et al. Cerebral embolic protection in TAVI: friend or foe. Interv Cardiol Rev. 2019;14:22.
   PubMedGoogle Scholar
• Puri R, Auffret V, Rodés-Cabau J. Bioprosthetic valve thrombosis. J Am Coll Cardiol. 2017;69:2193–2211.
   PubMed Web of Science ®Google Scholar
• Dangas GD, Weitz JI, Giustino G, et al. Prosthetic heart valve thrombosis. J Am Coll Cardiol. [Internet]. 2016 68:2670–2689. [cited 2018 Jan 20]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27978952
   PubMed Web of Science ®Google Scholar
• Capodanno D, Petronio AS, Prendergast B, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interven. Eur J Cardiothorac Surg. 2017;52:408–417.
   PubMed Web of Science ®Google Scholar
• Sondergaard L, De Backer O, Kofoed KF, et al. Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves. Eur Heart J. 2017;38:2201–2207.
   PubMed Web of Science ®Google Scholar
• Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389:2383–2392.
   PubMed Web of Science ®Google Scholar
• Franzone A, Pilgrim T, Haynes AG, et al. Transcatheter aortic valve thrombosis: incidence, clinical presentation and long-term outcomes. Eur Hear J - Cardiovasc Imaging. 2018;19:398–404.
   PubMed Web of Science ®Google Scholar
• Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart valve thrombosis after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10:686–697.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab M, Simonato M, Latib A, et al. Clinical Valve Thrombosis After Transcatheter Aortic Valve-in-Valve Implantation. Circ Cardiovasc Interv. 2018;11:e006730.
   PubMed Web of Science ®Google Scholar
• Latib A, Naganuma T, Abdel-Wahab M, et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv.  2015 Apr;8(4). pii: e001779. doi: 10.1161/CIRCINTERVENTIONS.114.001779.
   Web of Science ®Google Scholar
• Egbe AC, Pislaru SV, Pellikka PA, et al. Bioprosthetic valve thrombosis versus structural failure. J Am Coll Cardiol. 2015;66:2285–2294.
   PubMed Web of Science ®Google Scholar
• Vahidkhah K, Barakat M, Abbasi M, et al. Valve thrombosis following transcatheter aortic valve replacement: significance of blood stasis on the leaflets. Eur J Cardio-Thorac Surg. 2017;51:ezw407.
   Web of Science ®Google Scholar
• Ducci A, Tzamtzis S, Mullen MJ, et al. Hemodynamics in the Valsalva sinuses after transcatheter aortic valve implantation (TAVI). J Heart Valve Dis. 2013;22:688–696.
   PubMed Web of Science ®Google Scholar
• Del Trigo M, Muñoz-Garcia AJ, Wijeysundera HC, et al. Incidence, timing, and predictors of valve hemodynamic deterioration after transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;67:644–655.
   PubMed Web of Science ®Google Scholar
• Overtchouk P, Guedeney P, Rouanet S, et al. Long-term mortality and early valve dysfunction according to anticoagulation use. J Am Coll Cardiol. 2019;73:13–21.
   PubMed Web of Science ®Google Scholar
• Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–2024.
   PubMed Web of Science ®Google Scholar
• Pache G, Schoechlin S, Blanke P, et al. Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J. 2016;37:2263–2271.
   PubMed Web of Science ®Google Scholar
• Hafiz AM, Kalra A, Ramadan R, et al. Clinical or symptomatic leaflet thrombosis following transcatheter aortic valve replacement: insights from the U.S. FDA MAUDE database. Struct Hear. 2017;1:256–264.
   Google Scholar
• Makki N, Shreenivas S, Kereiakes D, et al. A meta-analysis of reduced leaflet motion for surgical and transcatheter aortic valves: relationship to cerebrovascular events and valve degeneration. Cardiovasc Revascularization Med. 2018;19:868–873.
   PubMed Web of Science ®Google Scholar
• Hansson NC, Grove EL, Andersen HR, et al. Transcatheter aortic valve thrombosis incidence, predisposing factors, and clinical implications. J Am Coll Cardiol. 2016 Nov 8;68(19):2059-2069. doi: 10.1016/j.jacc.2016.08.010.
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Deepak, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736–2747.
   PubMed Web of Science ®Google Scholar
• Guedeney P, Mehran R, Collet J-P, et al. Antithrombotic therapy after transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2019;12:e007411.
   PubMed Web of Science ®Google Scholar
• Horiuchi H, Doman T, Kokame K, et al. Acquired von Willebrand Syndrome Associated with Cardiovascular Diseases. J Atheroscler Thromb. 2019;26:303–314.
   PubMed Web of Science ®Google Scholar
• Desai R, Parekh T, Singh S, et al. Alarming increasing trends in hospitalizations and mortality with Heyde’s Syndrome: a nationwide inpatient perspective (2007 to 2014). Am J Cardiol. 2019;123:1149–1155.
   PubMed Web of Science ®Google Scholar
• Sannino A, Gargiulo G, Schiattarella GG, et al. A meta-analysis of the impact of pre-existing and new-onset atrial fibrillation on clinical outcomes in patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2016;12:e1047–e1056.
   PubMed Web of Science ®Google Scholar
• Gargiulo G, Capodanno D, Sannino A, et al. New-onset atrial fibrillation and increased mortality after transcatheter aortic valve implantation: A causal or spurious association? Int J Cardiol. 2016;203:264–266.
   PubMed Web of Science ®Google Scholar
• Nguyen TN, Morel-Kopp M-C, Pepperell D, et al. The impact of frailty on coagulation and responses to warfarin in acute older hospitalised patients with atrial fibrillation: a pilot study. Aging Clin Exp Res. 2017;29:1129–1138.
   PubMed Web of Science ®Google Scholar
• Alonso Salinas GL, Sanmartín Fernández M, Pascual Izco M, et al. Frailty predicts major bleeding within 30 days in elderly patients with Acute Coronary Syndrome. Int J Cardiol. 2016;222:590–593.
   PubMed Web of Science ®Google Scholar
• Maes F, Stabile E, Ussia GP, et al. Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implantation. Am J Cardiol. 2018;122:310–315.
   PubMedGoogle Scholar
• Konigstein M, Ben-Assa E, Banai S, et al. Periprocedural bleeding, acute kidney injury, and long-term mortality after transcatheter aortic valve implantation. Can J Cardiol. 2015;31:56–62.
   PubMed Web of Science ®Google Scholar
• Hayashida K, Lefèvre T, Chevalier B, et al. Transfemoral aortic valve implantation. JACC Cardiovasc Interv. 2011;4:851–858.
   PubMed Web of Science ®Google Scholar
• Borz B, Durand E, Godin M, et al. Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis. Heart. 2013;99:860–865.
   PubMed Web of Science ®Google Scholar
• De Larochellière H, Puri R, Eikelboom JW, et al. Blood disorders in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12:1–11.
   PubMed Web of Science ®Google Scholar
• Hernández-Enríquez M, Regueiro A, Romaguera R, et al. Thrombocytopenia after transcatheter aortic valve implantation. A comparison between balloon-expandable and self-expanding valves. Catheter Cardiovasc Interv. 2019 Jun 1;93(7):1344-1351. doi: 10.1002/ccd.27907.
   PubMedGoogle Scholar
• Mitrosz M, Chlabicz M, Hapaniuk K, et al. Thrombocytopenia associated with TAVI—the summary of possible causes. Adv Med Sci. 2017;62:378–382.
   PubMed Web of Science ®Google Scholar
• Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease. J Am Coll Cardiol. 2014;63:e57–e185.
   PubMed Web of Science ®Google Scholar
• Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2017;2017(135):e1159–e1195.
   Google Scholar
• Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. [Internet]. 2017 38:2739–2791. [cited 2018 Mar 17]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/28886619
   PubMed Web of Science ®Google Scholar
• Webb J, Rodés-Cabau J, Fremes S, et al. Transcatheter aortic valve implantation: a canadian cardiovascular society position statement. Can J Cardiol. 2012;28:520–528.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Alfonso F, Levine GN, et al. ACC/AHA Versus ESC guidelines on dual antiplatelet therapy. J Am Coll Cardiol. 2018;72:2915–2931.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Angiolillo DJ. Tailoring antiplatelet therapy in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12:33–37.
   PubMed Web of Science ®Google Scholar
• Cerrato E, Nombela-Franco L, Nazif TM, et al. Evaluation of current practices in transcatheter aortic valve implantation: the WRITTEN (WoRldwIde TAVI ExperieNce) survey. Int J Cardiol. [Internet]. 2017 228:640–647. [cited 2018 Mar 17]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27883975
   PubMed Web of Science ®Google Scholar
• Ferlini M, Mauri S, Rossini R. Dual antiplatelet therapy after TAVR: A drop in the bucket? Int J Cardiol. 2019;280:46–48.
   PubMed Web of Science ®Google Scholar
• Grube E, Laborde JC, Gerckens U, et al. Percutaneous Implantation of the CoreValve Self-Expanding Valve Prosthesis in High-Risk Patients With Aortic Valve Disease. Circulation. 2006;114:1616–1624.
   PubMed Web of Science ®Google Scholar
• Mangieri A, Jabbour RJ, Montalto C, et al. Single-antiplatelet therapy in patients with contraindication to dual-antiplatelet therapy after transcatheter aortic valve implantation. Am J Cardiol. 2017;119:1088–1093.
   PubMed Web of Science ®Google Scholar
• Ichibori Y, Mizote I, Maeda K, et al. Clinical outcomes and bioprosthetic valve function after transcatheter aortic valve implantation under dual antiplatelet therapy vs. Aspirin Alone Circ J. 2017;81:397–404.
   PubMed Web of Science ®Google Scholar
• Hioki H, Watanabe Y, Kozuma K, et al. Pre-procedural dual antiplatelet therapy in patients undergoing transcatheter aortic valve implantation increases risk of bleeding. Heart. 2017;103:361–367.
   PubMed Web of Science ®Google Scholar
• Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2011;108:1772–1776.
   PubMed Web of Science ®Google Scholar
• Stabile E, Pucciarelli A, Cota L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: A pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol. 2014;174:624–627.
   PubMed Web of Science ®Google Scholar
• Rodés-Cabau J, Masson J-B, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve. JACC Cardiovasc Interv. 2017;10:1357–1365.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Angiolillo DJ. Antithrombotic therapy for prevention of cerebral thromboembolic events after transcatheter aortic valve replacement. JACC Cardiovasc Interv. [Internet]. 2017 [cited 2018 Jan 30];10:1366–1369. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28527775
   PubMedGoogle Scholar
• Ahmad Y, Ahmad@ Y, Demir O, et al. Optimal antiplatelet strategy after transcatheter aortic valve implantation: a meta-analysis. Open Heart. 2017;5:748.
   Web of Science ®Google Scholar
• Sherwood MW, Vemulapalli S, Harrison JK, et al. Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: insights from the STS/ACC TVT Registry. Am Heart J. 2018;204:9–16.
   PubMed Web of Science ®Google Scholar
• Nijenhuis VJ, Brouwer J, Søndergaard L, et al. Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. Heart. 2019. heartjnl-2018–314313.
   PubMedGoogle Scholar
• Marwan M, Mekkhala N, Göller M, et al. Leaflet thrombosis following transcatheter aortic valve implantation. J Cardiovasc Comput Tomogr. 2018;12:8–13.
   PubMed Web of Science ®Google Scholar
• Abdul-Jawad Altisent O, Durand E, Muñoz-García AJ, et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2016;9:1706–1717.
   PubMed Web of Science ®Google Scholar
• Vora AN, Dai D, Matsuoka R, et al. Incidence, management, and associated clinical outcomes of new-onset atrial fibrillation following transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11:1746–1756.
   PubMed Web of Science ®Google Scholar
• Geis N, Kiriakou C, Chorianopoulos E, et al. Feasibility and safety of vitamin K antagonist monotherapy in atrial fibrillation patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2017;12:2058–2066.
   PubMed Web of Science ®Google Scholar
• Geis NA, Kiriakou C, Chorianopoulos E, et al. NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation. Clin Res Cardiol. 2018;107:799–806.
   PubMed Web of Science ®Google Scholar
• Lamberts M, Gislason GH, Lip GYH, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. [Internet]. 2014 129:1577–1585. [cited 2017 Oct 22]; Available from: http://circ.ahajournals.org/cgi/doi/10.1161/CIRCULATIONAHA.113.004834
   PubMed Web of Science ®Google Scholar
• Aboyans V, Ricco J-B, Bartelink M-LE-L, et al. Editor’s choice – 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55:305–368.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423–2434.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention.. Am Heart J. [Internet]. 2015;169:472–8.e5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25819853
   PubMed Web of Science ®Google Scholar
• Park S-J. ADAPT-TAVR anticoagulant versus dual antiplatelet therapy for preventing leaflet thrombosis and cerebral embolization after transcatheter aortic valve replacement. (NCT03284827).
   Google Scholar
• Windecker S, Tijssen J, Giustino G, et al. Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study. Am Heart J. [Internet]. 2017 184:81–87. [cited 2018 Jan 20]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S000287031630240X
   PubMed Web of Science ®Google Scholar
• Van Mieghem NM, Unverdorben M, Valgimigli M, et al. Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—rationale and design of the ENVISAGE-TAVI AF trial. Am Heart J. 2018;205:63–69.
   PubMed Web of Science ®Google Scholar
• Collet J-P, Berti S, Cequier A, et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial. Am Heart J. [Internet]. 2018 200:44–50. [cited 2018 May 6]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002870318300802
   PubMed Web of Science ®Google Scholar
• Seeger J, Gonska B, Rodewald C, et al. Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement. JACC Cardiovasc Interv. 2017;10:66–74.
   PubMed Web of Science ®Google Scholar
• GALILEO (global study comparing a rivaroxaban-based antithrombotic strategy to an antiplatelet-based strategy after transcatheter aortIc vaLve rEplacement to optimize clinical outcomes). (NCT02556203).
   Google Scholar
• Landmesser U. EARTH-TAVR (evaluation of cerebral thrombembolism after TAVR). (NCT02758964).
   Google Scholar
• Sondergaard L GALILEO-4D (comparison of a rivaroxaban-based strategy with an antiplatelet-based strategy following successful tavr for the prevention of leaflet thickening and reduced leaflet motion as evaluated by four-dimensional, Volume-rendered Computed Tomography.
   Google Scholar
• Nijenhuis VJ, Bennaghmouch N, Hassell M, et al. Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation. Am Heart J. [Internet]. 2016 173:77–85. [cited 2018 Jan 31]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002870315006651
   PubMed Web of Science ®Google Scholar
• Ten Berg JM POPular-TAVI (antiplatelet therapy for patients undergoing transcatheter aortic valve implantation); (NCT02247128).
   Google Scholar
• Hernandez JM. AUREA (dual antiplatelet therapy versus oral anticoagulation for a short time to prevent cerebral embolism after TAVI). (NCT01642134).
   Google Scholar
• Capodanno D, Mehran R, Valgimigli M, et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol. [Internet]. 2018;15:480–496. Available from: https://doi.org/10.1038/s41569-018-0049-1
   PubMed Web of Science ®Google Scholar
• Leroux L. TICTAVI (safety profile evaluation of TICagrelor alone compared to a combination of lysine acetylsalicylate-clopidogrel in the context of transcatheter aortic valve implantation). (NCT02817789).
   Google Scholar
• Emmanouil V. PTOLEMAIOS (A trial to assess the safety and efficacy of prophylactic ticagrelOr with acetylsalicylic acid versus CLopidogrel with acetylsalicylic acid in the development of cerebrovascular EMbolic events during TAVI). (NCT02989558).
   Google Scholar
• Cayla G. AVATAR (anticoagulation alone versus anticoagulation and aspirin following transcatheter aortic valve interventions (1:1). (NCT02735902).
   Google Scholar
• Vaksman RS. LRT (strategies to prevent transcatheter heart valve dysfunction in low risk transcatheter aortic valve replacement. (NCT03557242).
   Google Scholar
• ENVISAGE-TAVI AF (edoxaban compared to standard care after heart valve replacement using a catheter in patients with atrial fibrillation. (NCT02943785).
   Google Scholar
• Collet J-P. ATLANTIS(anti-thrombotic strategy after trans-aortic valve implantation for aortic stenosis. (NCT02664649).
   Google Scholar
• Capodanno D, Angiolillo DJDJ. Tailoring duration of DAPT with risk scores. Lancet. [Internet]. 2017 389:987–989. [cited 2017 Jul 13]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/28291000
   PubMed Web of Science ®Google Scholar
• Buccheri S, D’Arrigo P, Franchina G, et al. Risk stratification in patients with coronary artery disease: a practical walkthrough in the landscape of prognostic risk models. Interv Cardiol Rev. 2018;13:112.
   PubMedGoogle Scholar
• Capodanno D, Greco A. Risk Stratification for Bleeding in the Elderly with Acute Coronary Syndrome: Not So Simple. Thromb Haemost. 2018;118.
   Google Scholar
• Lauten A. DAPT-TAVI (dual antiplatelet therapies for prevention of periinterventional embolic events in TAVI). (NCT03001960).
   Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in Individual Responsiveness to Clopidogrel. J Am Coll Cardiol. [Internet]. 2007 49:1505–1516. [cited 2018 Jan 1]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/17418288
   PubMed Web of Science ®Google Scholar
• Bömicke T, Valina CM, Stratz C, et al. On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel. Thromb Haemost. [Internet]. 2017;117:1644–1650. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28382368
   PubMed Web of Science ®Google Scholar
• de Carvalho L, Fong A, Troughton R, et al. Prognostic implications of dual platelet reactivity testing in acute coronary syndrome. Thromb Haemost. 2018;46:415–426.
   Google Scholar
• Polzin A, Schleicher M, Seidel H, et al. High on-treatment platelet reactivity in transcatheter aortic valve implantation patients. Eur J Pharmacol. [Internet]. 2015;751:24–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25641745
   PubMed Web of Science ®Google Scholar
• Orvin K, Eisen A, Perl L, et al. Platelet reactivity in patients undergoing transcatheter aortic valve implantation. J Thromb Thrombolysis. 2016;42:11–18.
   PubMed Web of Science ®Google Scholar
• Czerwińska-Jelonkiewicz K, Witkowski A, Dąbrowski M, et al. The role of platelet reactivity assessment in dual antiplatelet prophylaxis after transcatheter aortic valve implantation. Arch Cardiovasc Dis. 2018;111:233–245.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Kozuma K, Ishikawa S, et al. Hyper-response to clopidogrel in Japanese patients undergoing transcatheter aortic valve implantation. Int Heart J. 2016;57:190–197.
   PubMed Web of Science ®Google Scholar
• Kibler M, Marchandot B, Messas N, et al. CT-ADP point-of-care assay predicts 30-day paravalvular aortic regurgitation and bleeding events following transcatheter aortic valve replacement. Thromb Haemost. 2018;118:893–905.
   PubMed Web of Science ®Google Scholar
• Gross L, Jochheim D, Nitschke T, et al. Platelet reactivity and early outcomes after transfemoral aortic valve implantation. Thromb Haemost. [Internet]. 2018;118:1832–1838. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30235476
   PubMed Web of Science ®Google Scholar
• Capodanno D, Greco A. Platelet function testing after transcatheter aortic valve implantation. Thromb Haemost. [Internet]. 2018;118:1681–1685. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30273951
   PubMed Web of Science ®Google Scholar
• Jimenez Diaz VA, Tello-Montoliu A, Moreno R, et al. Assessment of platelet Reactivity after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12:22–32.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. Dual antiplatelet therapy guided by platelet function testing. Lancet. [Internet]. 2017;390:1718–1720. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28855079
   PubMed Web of Science ®Google Scholar
• Rymuza B, Zbroński K, Scisło P, et al. Thromboelastography for predicting bleeding in patients with aortic stenosis treated with transcatheter aortic valve implantation. Kardiol Pol. 2018;76(2):418-425.
   Web of Science ®Google Scholar
• Pottgiesser T RISTRATAVI (risk stratification post TAVI using TEG). (NCT03649594).
   Google Scholar
• Parker RJ, Eley KA, Von Kier S, et al. Functional fibrinogen to platelet ratio using thromboelastography as a predictive parameter for thrombotic complications following free tissue transfer surgery: A preliminary study. Microsurgery. 2012;32:512–519.
   PubMed Web of Science ®Google Scholar
• Krzanicki D, Sugavanam A, Mallett S. Intraoperative hypercoagulability during liver transplantation as demonstrated by thromboelastography. Liver Transplant. 2013;19:852–861.
   PubMed Web of Science ®Google Scholar
• Saad M, Nairooz R, Pothineni NVK, et al. Long-term outcomes with transcatheter aortic valve replacement in women compared with men. JACC Cardiovasc Interv. 2018;11:24–35.
   PubMedGoogle Scholar
• Szerlip M, Gualano S, Holper E, et al. Sex-specific outcomes of transcatheter aortic valve replacement with the SAPIEN 3 valve. JACC Cardiovasc Interv. 2018;11:13–20.
   PubMedGoogle Scholar
• Katz M, Carlos Bacelar Nunes Filho A, Caixeta A, et al. Gender-related differences on short- and long-term outcomes of patients undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2017;89:429–436.
   PubMed Web of Science ®Google Scholar
• Wang T-Y, Gracia E, Callahan S, et al. Gender disparities in management and outcomes following transcatheter aortic valve implantation with newer generation transcatheter valves. Am J Cardiol. 2019;123:1489–1493.
   PubMed Web of Science ®Google Scholar
• O’Connor SA, Morice M-C, Gilard M, et al. Revisiting sex equality with transcatheter aortic valve replacement outcomes. J Am Coll Cardiol. 2015;66:221–228.
   PubMed Web of Science ®Google Scholar
• Romano S, Buccheri S, Mehran R, et al. Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. Expert Opin Drug Saf. 2018;17:1041–1052.
   PubMed Web of Science ®Google Scholar
• Greco A, Capodanno D, Angiolillo DJ. The conundrum surrounding racial differences on ischaemic and bleeding risk with dual anti-platelet therapy. Thromb Haemost. 2019 Jan;119(1):9-13.
   PubMed Web of Science ®Google Scholar
• Yoon S-H, Ohno Y, Araki M, et al. Comparison of aortic root anatomy and calcification distribution between Asian and Caucasian patients who underwent transcatheter aortic valve implantation. Am J Cardiol. 2015;116:1566–1573.
   PubMed Web of Science ®Google Scholar
• McNeely C, Zajarias A, Fohtung R, et al. Racial comparisons of the outcomes of transcatheter and surgical aortic valve implantation using the medicare database. Am J Cardiol. 2018;122:440–445.
   PubMed Web of Science ®Google Scholar
• McHugh F, Ahmed K, Neylon A, et al. Antithrombotic management after transcatheter aortic valve implantation. J Thorac Dis. 2018;10:S3620.
   PubMed Web of Science ®Google Scholar
• Attinger-Toller A, Maisano F, Senn O, et al. One-stop shop. JACC Cardiovasc Interv. 2016;9:1487–1495.
   PubMedGoogle Scholar
• Kapadia SR WATCH-TAVR (WATCHMAN for patients with atrial fibrillation undergoing transcatheter aortic valve replacement). NCT03173534).
   Google Scholar
• Kibler M, Marchandot B, Messas N, et al. Primary hemostatic disorders and late major bleeding after transcatheter aortic valve replacement. J Am Coll Cardiol. 2018;72:2139–2148.
   PubMedGoogle Scholar
• McFadyen JD, Peter K. Novel antithrombotic drugs on the horizon. Circ Res. 2017;121:1133–1135.
   PubMed Web of Science ®Google Scholar
• McFadyen JD, Schaff M, Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol. [Internet]. 2018;15:181–191. Available from: http://www.nature.com/doifinder/10.1038/nrcardio.2017.206
   PubMed Web of Science ®Google Scholar